We’re in San Diego for AACR 2024!

Don’t miss Christian’s presentation on how our SITESEEKER platform can be deployed to identify novel #TPD mechanisms to support the development of new cancer therapies.

Learn more: rb.gy/x7bjd5

#TPD offers a promising new therapeutic modality to eliminate toxic or disease-associated targets from cells, with degradation based therapies such as #PROTACs and #MolecularGlues becoming an integral approach to tackling undruggable targets.

Learn more: rb.gy/1l8vkm

Next week, we're heading to AACR, joining scientists and healthcare professionals to share the latest advances in #cancer science.

Christian will be presenting on the systematic identification of novel #TPD mechanisms using our SITESEEKER platform: rb.gy/bz9lci

Molecular glues offer a promising new approach for degrader therapeutics by enhancing affinity between proteins to exhibit a therapeutic effect.

Ben spoke to Labiotech.eu, exploring the need for a systematic technology to discover new molecular glues: rb.gy/3z98lq

We have been shortlisted for the Cambridge Independent Science & Technology #LifeScience Company of the Year Award! 🎉
The award celebrates a pioneer in the life sciences in one of the world's most exciting #biotech hubs.
Congratulations to all finalists: rb.gy/n28eb8

This week, we're at TPD Summit Europe, exploring novel degrader mechanisms, new E3 ligase discovery, and the rational discovery of #molecularglues .

Don’t miss Rich’s presentation 'PROTEINi Screening for bifunctional #degrader discovery'!

Learn more: rb.gy/q1nx79

Neil Torbett is at BIOEurope Spring, hearing about the latest advancements in #lifesciences from innovative start ups and academic researchers.

There’s still time to schedule a meeting to learn more about our SITESEEKER Discovery Platform: rb.gy/q1nx79

Next week, our team will be at BIO Europe. This year's event will explore global life science ecosystems, with updates on progress in therapeutic areas such as #Oncology .

Contact us to learn find out about our pipeline of E3 ligases for degrader drugs: rb.gy/q1nx79

Today, we’re celebrating International Women’s Day!

We spoke with Dr Rebecca Teague and Dr Poonam Shah to discuss their experiences as Women in STEM, and how we can offer more support to women looking to enter the life science industry.

Read more 🔽
#IWD2024 #WomeninSTEM

With all 6 parts of the Scrip Asks series now live, did you catch our CTO's predictions for the 2024 biopharma industry?

Ben explored how we can harness new targeting modalities, such as #MolecularGlues , to design new degrader #therapeutics .

Read more: rb.gy/d8h20n

Did you spot Dr Neil Torbett in Labiotech.eu's recent article on 2024 biotech trends?

Neil shared his thoughts on how the next year will be transformative for the design and development of degrader therapeutics: rb.gy/4x9wwy

#TPD #DrugDiscovery #MolecularGlues

Interested in finding out more about the discovery of bifunctional #degraders ?

Join Dr Rich Boyce at TPD Summit Europe to learn how we are using our PROTEINi technology to accelerate small molecule #drugdesign and development.

Check out the full agenda: rb.gy/evo3yv

Ben Cross spoke to Scrip about his 2024 predictions for the #biopharma industry, and how we can harness new targeting modalities.

With bivalent drugs such as PROTACs in development, attention is shifting to smaller #MolecularGlue medicines.

Read more: rb.gy/d8h20n

It’s National #Apprenticeship Week!

To mark this, we spoke with Sajaana about why she chose to do an apprenticeship, and her experiences working at Phoremost. 🔽

2024 promises to be an exciting year for life sciences, with a focus on collaborations with big pharma in the #Oncology space to bring more investment to #Cambridge , and increased interest in the role of AI in #DrugDiscovery .

Read more in Business Weekly: rb.gy/vp5f68

“Molecular glues are an exciting new approach to degrader therapeutics”

In a recent Labiotech.eu article, Neil shared his thoughts on how the next year will be transformative for the #TPD space, in particular for the development of #MolecularGlues : rb.gy/4x9wwy

Thank you to Business Weekly for including us in the 2024 New Years Honours!

The list celebrates Cambridge’s #lifescience sector, recognising contributions to the UK economy and job markets, and showcasing advances in healthcare and #drugdiscovery : rb.gy/wnbj35

Have you read our recent blog?

Neil Torbett reflects on PhoreMost’s achievements from 2023, including reaching scientific milestones, establishing our pipeline of degrader-focussed #drugdiscovery programmes, and collaborations across #biotech and #pharma : rb.gy/x49r85

Our team is at #JPM24 , looking forward to a busy week of partnering meetings and presentations from innovative #biotech and #pharma companies.

To learn more about our SITESEEKER Discovery platform and our pipeline of novel #degraders , get in touch: rb.gy/pl7qd1

Next week, we’re headed to #SanFrancisco for #JPM2024 , connecting with #biotech investors and partners, and sharing updates on our progress in the field of #TPD .

Get in touch to learn about our pipeline of degrader-focussed #drugdiscovery programmes: rb.gy/pl7qd1